Australia markets closed

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4529-0.0370 (-7.55%)
At close: 04:00PM EDT

Catalyst Biosciences, Inc.

611 Gateway Blvd.
Suite 710
South San Francisco, CA 94080
United States
650 871 0761

Full-time employees7

Key executives

NameTitlePayExercisedYear born
Dr. Nassim Usman Ph.D.Pres, CEO & Director1.75MN/A1960
Ms. Seline E. Miller CPASr. VP of Fin., Interim Chief Financial & Principal Accounting Officer707.55kN/A1969
Ms. Ana KaporSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Corporate governance

Catalyst Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.